Find Abaloparatide Acetate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Tymlos, Ba058, Unii-avk0i6hy2u, Bim-44058, Abaloparatide [usan:inn], Abaloparatide-sc
Molecular Formula
C174H300N56O49
Molecular Weight
3961  g/mol
InChI Key
BVISQZFBLRSESR-XSCWXTNMSA-N

Abaloparatide Acetate
Abaloparatide is a 34 amino acid synthetic analog of human parathyroid hormone-related protein (PTHrP) (PTHrP(1-34) analog), with bone-growing and bone density conserving activities. Upon subcutaneous administration, abaloparatide acts similar to PTHrP and targets, binds to and activates parathyroid hormone 1 (PTH1) receptor (PTH1R), a G protein-coupled receptor (GPCR) expressed in osteoblasts and bone stromal cells. PTH1R activates the cyclic AMP (cAMP) signaling pathway and the bone anabolic signaling pathway, leading to bone growth, increased bone mineral density (BMD) and volume. This correlates with increased bone mass and strength and prevents or treats osteoporosis and decreases fractures.
1 2D Structure

Abaloparatide Acetate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]acetyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
2.1.2 InChI
InChI=1S/C174H300N56O49/c1-26-93(20)136(228-165(274)126(80-232)224-141(250)101(39-28-32-56-176)200-129(236)78-195-140(249)100(38-27-31-55-175)201-161(270)123(73-133(243)244)223-160(269)121(71-98-76-190-82-197-98)220-158(267)118(68-90(14)15)216-155(264)114(64-86(6)7)213-148(257)107(45-50-127(180)234)207-159(268)120(70-97-75-189-81-196-97)219-151(260)111(49-54-132(241)242)209-164(273)125(79-231)225-167(276)135(92(18)19)227-139(248)94(21)179)168(277)210-108(46-51-128(181)235)149(258)222-124(74-134(245)246)162(271)217-112(62-84(2)3)152(261)205-105(44-37-61-194-173(187)188)143(252)203-103(42-35-59-192-171(183)184)142(251)204-104(43-36-60-193-172(185)186)144(253)206-110(48-53-131(239)240)150(259)214-115(65-87(8)9)154(263)215-113(63-85(4)5)153(262)208-109(47-52-130(237)238)147(256)202-102(40-29-33-57-177)145(254)211-116(66-88(10)11)156(265)218-119(69-91(16)17)166(275)230-174(24,25)170(279)226-106(41-30-34-58-178)146(255)212-117(67-89(12)13)157(266)221-122(72-99-77-191-83-198-99)163(272)229-137(96(23)233)169(278)199-95(22)138(182)247/h75-77,81-96,100-126,135-137,231-233H,26-74,78-80,175-179H2,1-25H3,(H2,180,234)(H2,181,235)(H2,182,247)(H,189,196)(H,190,197)(H,191,198)(H,195,249)(H,199,278)(H,200,236)(H,201,270)(H,202,256)(H,203,252)(H,204,251)(H,205,261)(H,206,253)(H,207,268)(H,208,262)(H,209,273)(H,210,277)(H,211,254)(H,212,255)(H,213,257)(H,214,259)(H,215,263)(H,216,264)(H,217,271)(H,218,265)(H,219,260)(H,220,267)(H,221,266)(H,222,258)(H,223,269)(H,224,250)(H,225,276)(H,226,279)(H,227,248)(H,228,274)(H,229,272)(H,230,275)(H,237,238)(H,239,240)(H,241,242)(H,243,244)(H,245,246)(H4,183,184,192)(H4,185,186,193)(H4,187,188,194)/t93-,94-,95-,96+,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,135-,136-,137-/m0/s1
2.1.3 InChI Key
BVISQZFBLRSESR-XSCWXTNMSA-N
2.1.4 Canonical SMILES
CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C)(C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC1=CN=CN1)C(=O)NC(C(C)O)C(=O)NC(C)C(=O)N)NC(=O)C(CO)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC2=CN=CN2)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)N)NC(=O)C(CC3=CN=CN3)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(C)N
2.1.5 Isomeric SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N
2.2 Synonyms
2.2.1 MeSH Synonyms

1. Ba058

2. Tymlos

2.2.2 Depositor-Supplied Synonyms

1. Tymlos

2. Ba058

3. Unii-avk0i6hy2u

4. Bim-44058

5. Abaloparatide [usan:inn]

6. Abaloparatide-sc

7. Avk0i6hy2u

8. Chembl4084894

9. Bdbm50246337

10. C2.29-methyl(22-l-glutamic Acid(f>e),23-l-leucine(f>l),25-l-glutamic Acid(h>e),26-l-lysine(h>k),28-l-leucine(i>l),30-l-lysine(e>k),31-l-leucine(i>l))human Parathyroid Hormone-related Protein-(1-34)-proteinamide

2.3 Create Date
2014-08-23
3 Chemical and Physical Properties
Molecular Weight 3961 g/mol
Molecular Formula C174H300N56O49
XLogP3-20.9
Hydrogen Bond Donor Count61
Hydrogen Bond Acceptor Count60
Rotatable Bond Count145
Exact Mass3959.2738250 g/mol
Monoisotopic Mass3958.2704702 g/mol
Topological Polar Surface Area1740 Ų
Heavy Atom Count279
Formal Charge0
Complexity9310
Isotope Atom Count0
Defined Atom Stereocenter Count34
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Bone Density Conservation Agents

Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)


Drugs in Development

read-more
read-more

Details:

Under the licensing agreement, Radius granted Theramex the exclusive commercialization rights to Eladynos (abaloparatide), indicated for the treatment of osteoporosis in postmenopausal


Lead Product(s): Abaloparatide Acetate

Therapeutic Area: Musculoskeletal Brand Name: Eladynos

Study Phase: Approved FDFProduct Type: Peptide

Sponsor: Theramex

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement December 09, 2024

blank

01

AMWC Asia-TDAC
Not Confirmed
AMWC Asia-TDAC
Not Confirmed

Details : Under the licensing agreement, Radius granted Theramex the exclusive commercialization rights to Eladynos (abaloparatide), indicated for the treatment of osteoporosis in postmenopausal

Product Name : Eladynos

Product Type : Peptide

Upfront Cash : Undisclosed

December 09, 2024

blank

Details:

Theramex will commercialise and distribute Eladynos (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures on an exclusive basis in the European Economic Area, UK , Australia and Brazil.


Lead Product(s): Abaloparatide Acetate

Therapeutic Area: Musculoskeletal Brand Name: Tymlos

Study Phase: Approved FDFProduct Type: Peptide

Sponsor: Theramex

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 20, 2023

blank

02

AMWC Asia-TDAC
Not Confirmed
AMWC Asia-TDAC
Not Confirmed

Details : Theramex will commercialise and distribute Eladynos (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures on an exclusive basis in the European Economic Area, UK , A...

Product Name : Tymlos

Product Type : Peptide

Upfront Cash : Undisclosed

March 20, 2023

blank

Details:

Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.


Lead Product(s): Abaloparatide Acetate

Therapeutic Area: Musculoskeletal Brand Name: Tymlos

Study Phase: Approved FDFProduct Type: Peptide

Sponsor: Gurnet Point Capital

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition August 15, 2022

blank

03

AMWC Asia-TDAC
Not Confirmed
AMWC Asia-TDAC
Not Confirmed

Details : Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Product Name : Tymlos

Product Type : Peptide

Upfront Cash : Undisclosed

August 15, 2022

blank

Details:

The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.


Lead Product(s): Abaloparatide Acetate

Therapeutic Area: Musculoskeletal Brand Name: Tymlos

Study Phase: Approved FDFProduct Type: Peptide

Sponsor: Gurnet Point Capital

Deal Size: $890.0 million Upfront Cash: $547.0 million

Deal Type: Acquisition August 15, 2022

blank

04

AMWC Asia-TDAC
Not Confirmed
AMWC Asia-TDAC
Not Confirmed

Details : The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.

Product Name : Tymlos

Product Type : Peptide

Upfront Cash : $547.0 million

August 15, 2022

blank

Details:

The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.


Lead Product(s): Abaloparatide Acetate

Therapeutic Area: Musculoskeletal Brand Name: Tymlos

Study Phase: Approved FDFProduct Type: Peptide

Sponsor: Gurnet Point Capital

Deal Size: $890.0 million Upfront Cash: $547.0 million

Deal Type: Acquisition June 23, 2022

blank

05

AMWC Asia-TDAC
Not Confirmed
AMWC Asia-TDAC
Not Confirmed

Details : The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.

Product Name : Tymlos

Product Type : Peptide

Upfront Cash : $547.0 million

June 23, 2022

blank

Details:

The data for spine BMD vs. baseline showed abalo-TDS had a 7.1% increase vs. TYMLOS (abaloparatide) +10.9%, both considered clinically meaningful. Despite missing the non-inferiority margin, the transdermal system demonstrated a bone building benefit to patients.


Lead Product(s): Abaloparatide Acetate

Therapeutic Area: Musculoskeletal Brand Name: Tymlos

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 06, 2022

blank

06

AMWC Asia-TDAC
Not Confirmed
AMWC Asia-TDAC
Not Confirmed

Details : The data for spine BMD vs. baseline showed abalo-TDS had a 7.1% increase vs. TYMLOS (abaloparatide) +10.9%, both considered clinically meaningful. Despite missing the non-inferiority margin, the transdermal system demonstrated a bone building benefit to ...

Product Name : Tymlos

Product Type : Peptide

Upfront Cash : Inapplicable

January 06, 2022

blank

Details:

Company announced phase 3 topline results from the wearABLe study did not meet its primary endpoint evaluating the NI of BA058 (abaloparatide) in postmenopausal women with osteoporosis.


Lead Product(s): Abaloparatide Acetate

Therapeutic Area: Musculoskeletal Brand Name: Tymlos

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 12, 2021

blank

07

AMWC Asia-TDAC
Not Confirmed
AMWC Asia-TDAC
Not Confirmed

Details : Company announced phase 3 topline results from the wearABLe study did not meet its primary endpoint evaluating the NI of BA058 (abaloparatide) in postmenopausal women with osteoporosis.

Product Name : Tymlos

Product Type : Peptide

Upfront Cash : Inapplicable

August 12, 2021

blank

Details:

Endo obtained the rights to abaloparatide-subcutaneous injection and abaloparatide-transdermal patch, a novel formulation and route of administration currently undergoing clinical development. Endo, will be responsible for all commercial activities related to abaloparatide.


Lead Product(s): Abaloparatide Acetate

Therapeutic Area: Musculoskeletal Brand Name: BA058

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Endo International

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement May 01, 2021

blank

08

PALADIN LABS

Canada
arrow
AMWC Asia-TDAC
Not Confirmed

PALADIN LABS

Canada
arrow
AMWC Asia-TDAC
Not Confirmed

Details : Endo obtained the rights to abaloparatide-subcutaneous injection and abaloparatide-transdermal patch, a novel formulation and route of administration currently undergoing clinical development. Endo, will be responsible for all commercial activities relat...

Product Name : BA058

Product Type : Peptide

Upfront Cash : Undisclosed

May 01, 2021

blank

Details:

The study was designed to look at the effects on bone mineral density of abaloparatide delivered via a novel transdermal device (“abaloparatide-patch”) compared with the current subcutaneous formulation, marketed as TYMLOS®.


Lead Product(s): Abaloparatide Acetate

Therapeutic Area: Musculoskeletal Brand Name: Tymlos

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 09, 2020

blank

09

AMWC Asia-TDAC
Not Confirmed
AMWC Asia-TDAC
Not Confirmed

Details : The study was designed to look at the effects on bone mineral density of abaloparatide delivered via a novel transdermal device (“abaloparatide-patch”) compared with the current subcutaneous formulation, marketed as TYMLOS®.

Product Name : Tymlos

Product Type : Peptide

Upfront Cash : Inapplicable

August 09, 2020

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for / Abaloparatide Acetate API manufacturers, exporters & distributors?

Abaloparatide Acetate manufacturers, exporters & distributors 1

23

PharmaCompass offers a list of Abaloparatide Acetate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Abaloparatide Acetate manufacturer or Abaloparatide Acetate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Abaloparatide Acetate manufacturer or Abaloparatide Acetate supplier.

PharmaCompass also assists you with knowing the Abaloparatide Acetate API Price utilized in the formulation of products. Abaloparatide Acetate API Price is not always fixed or binding as the Abaloparatide Acetate Price is obtained through a variety of data sources. The Abaloparatide Acetate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Abaloparatide Acetate

Synonyms

Tymlos, Ba058, Unii-avk0i6hy2u, Bim-44058, Abaloparatide [usan:inn], Abaloparatide-sc

About Abaloparatide Acetate

Abaloparatide is a 34 amino acid synthetic analog of human parathyroid hormone-related protein (PTHrP) (PTHrP(1-34) analog), with bone-growing and bone density conserving activities. Upon subcutaneous administration, abaloparatide acts similar to PTHrP and targets, binds to and activates parathyroid hormone 1 (PTH1) receptor (PTH1R), a G protein-coupled receptor (GPCR) expressed in osteoblasts and bone stromal cells. PTH1R activates the cyclic AMP (cAMP) signaling pathway and the bone anabolic signaling pathway, leading to bone growth, increased bone mineral density (BMD) and volume. This correlates with increased bone mass and strength and prevents or treats osteoporosis and decreases fractures.

Abaloparatide Manufacturers

A Abaloparatide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Abaloparatide, including repackagers and relabelers. The FDA regulates Abaloparatide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Abaloparatide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Abaloparatide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Abaloparatide Suppliers

A Abaloparatide supplier is an individual or a company that provides Abaloparatide active pharmaceutical ingredient (API) or Abaloparatide finished formulations upon request. The Abaloparatide suppliers may include Abaloparatide API manufacturers, exporters, distributors and traders.

click here to find a list of Abaloparatide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Abaloparatide USDMF

A Abaloparatide DMF (Drug Master File) is a document detailing the whole manufacturing process of Abaloparatide active pharmaceutical ingredient (API) in detail. Different forms of Abaloparatide DMFs exist exist since differing nations have different regulations, such as Abaloparatide USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Abaloparatide DMF submitted to regulatory agencies in the US is known as a USDMF. Abaloparatide USDMF includes data on Abaloparatide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Abaloparatide USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Abaloparatide suppliers with USDMF on PharmaCompass.

Abaloparatide NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Abaloparatide as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Abaloparatide API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Abaloparatide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Abaloparatide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Abaloparatide NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Abaloparatide suppliers with NDC on PharmaCompass.

Abaloparatide GMP

Abaloparatide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Abaloparatide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Abaloparatide GMP manufacturer or Abaloparatide GMP API supplier for your needs.

Abaloparatide CoA

A Abaloparatide CoA (Certificate of Analysis) is a formal document that attests to Abaloparatide's compliance with Abaloparatide specifications and serves as a tool for batch-level quality control.

Abaloparatide CoA mostly includes findings from lab analyses of a specific batch. For each Abaloparatide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Abaloparatide may be tested according to a variety of international standards, such as European Pharmacopoeia (Abaloparatide EP), Abaloparatide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Abaloparatide USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty